|Bid||96.00 x 1800|
|Ask||97.14 x 900|
|Day's Range||93.87 - 101.76|
|52 Week Range||70.75 - 159.54|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.31|
The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45. Exact Sciences' (NASDAQ: EXAS) Cologuard®, referred to as sDNA-FIT, is included as a recommended screening option for all average-risk patients between the ages of 45 and 75.
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?
Exact Sciences (NASDAQ: EXAS) recently announced its first-quarter results. In this Motley Fool Live video recorded on May 5, Motley Fool contributors Keith Speights and Brian Orelli discuss why Exact Sciences doesn't have to worry too much about declining COVID-19 testing rates impacting its growth. Keith Speights: There is another company that reported earnings, I think yesterday, Exact Sciences reported earnings and had some pretty good results there, Brian.